Daily Cardiology Research Analysis
Analyzed 171 papers and selected 3 impactful papers.
Summary
Seven-year durability data from PARTNER 3 show comparable structural valve performance for TAVR versus surgery in low-risk aortic stenosis. A meta-analysis of 14 RCTs supports abbreviated (especially 3-month) DAPT in high-bleeding-risk PCI patients by reducing bleeding without increasing ischemic events. A large UK Biobank study reveals that IL-6 levels modify Lp(a)-associated coronary risk, highlighting an inflammation–lipoprotein interaction for precision prevention.
Research Themes
- Structural valve therapy durability and lifetime management
- Antithrombotic optimization in high-bleeding-risk PCI
- Inflammation–lipoprotein interactions for precision cardiovascular risk
Selected Articles
1. Seven-Year Valve Durability With Transcatheter or Surgical Aortic Valve Replacement: An Ad Hoc Analysis of the PARTNER 3 Randomized Clinical Trial.
In low-risk severe aortic stenosis, 7-year cumulative incidences of structural valve deterioration–related dysfunction, all-cause bioprosthetic valve failure, and reintervention were low and similar between TAVR and surgery. Thrombosis-related valve dysfunction (mostly subclinical) was more frequent after TAVR but rarely progressed to valve failure.
Impact: First robust randomized evidence extending comparative valve durability of TAVR vs surgery to 7 years in low-risk patients informs lifetime management decisions.
Clinical Implications: Supports TAVR as a durable option in low-risk patients through 7 years, while emphasizing surveillance for leaflet thrombosis and tailored antithrombotic strategies.
Key Findings
- Stage 2/3 SVD-related BVD: 7.3% (TAVR) vs 7.6% (surgery); HR 0.96 (95% CI 0.59–1.57).
- All-cause BVF: 6.9% vs 7.5%; HR 0.91 (95% CI 0.55–1.49).
- Valve reintervention: 6.0% vs 5.5%; HR 1.09 (95% CI 0.62–1.90).
- Thrombosis-related BVD higher with TAVR: 5.2% vs 0.9%; HR 5.52 (95% CI 1.92–15.85), mostly within 3 years and rarely progressing to BVF.
Methodological Strengths
- Randomized comparison with long (7-year) follow-up and competing risk analyses.
- Central echocardiographic assessments available in a large proportion of survivors.
Limitations
- Ad hoc durability analysis; not prespecified as a primary endpoint.
- Echocardiography at 7 years available in 80% of survivors; potential ascertainment bias.
Future Directions: Evaluate durability beyond 10 years, optimal antithrombotic strategies to mitigate subclinical leaflet thrombosis, and lifetime sequencing (TAVR-to-SAVR or redo-TAVR) in younger cohorts.
IMPORTANCE: As transcatheter aortic valve replacement (TAVR) is considered for younger and lower-risk populations, the durability of bioprosthetic valves is increasingly important. Limited data exist on long-term (7 years and beyond) valve durability. OBJECTIVE: To report 7-year valve durability outcomes for low-risk patients with symptomatic severe aortic stenosis treated with TAVR vs surgery. DESIGN, SETTING, AND PARTICIPANTS: Between March 2016 and October 2017, a total of 1000 patients were enrolled at 71 centers in the US and Canada and randomized to undergo TAVR vs surgery. The patient population for the present analysis consisted of all patients who underwent valve implantation (495 with TAVR and 453 with surgery). The last 7-year follow-up occurred in March 2025. INTERVENTIONS: Patients were randomized to balloon-expandable TAVR with the SAPIEN 3 valve or surgery with any commercially available valve.
2. Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-Analysis.
Across 14 RCTs (11,398 HBR patients), abbreviated DAPT reduced major or clinically relevant nonmajor bleeding (RR 0.71) and major bleeding (RR 0.76) versus standard DAPT, without increasing MACE (RR 0.97). Three-month DAPT appeared safer than 1-month regimens in one direct comparison; network estimates did not show significant differences between 1- and 3-month regimens.
Impact: Synthesizes randomized evidence guiding DAPT de-escalation in high-bleeding-risk PCI, directly informing contemporary practice and guideline updates.
Clinical Implications: In HBR PCI patients, consider 3-month DAPT to lower bleeding risk without compromising ischemic protection; 1-month regimens may be reserved for very high bleeding risk with careful ischemic surveillance.
Key Findings
- Abbreviated (1–3 months) vs standard (≥6 months) DAPT lowered MCRB (RR 0.71; 95% CI 0.55–0.92; P=.009).
- Major bleeding reduced with abbreviated DAPT (RR 0.76; 95% CI 0.59–0.99; P=.04).
- No increase in MACE with abbreviated DAPT (RR 0.97; 95% CI 0.81–1.16; P=.76).
- Single head-to-head trial suggested higher MACE with 1-month vs 3-month DAPT; network meta-analysis estimate was not significant (RR 1.28; 95% CI 0.96–1.72).
Methodological Strengths
- Pairwise and network meta-analyses restricted to randomized trials in HBR populations.
- Consistent bleeding and ischemic outcome definitions with robust sensitivity analyses.
Limitations
- Trial heterogeneity in stent platforms, P2Y12 choice, and HBR definitions.
- Limited direct head-to-head evidence comparing 1- vs 3-month DAPT.
Future Directions: Prospective trials refining patient selection for 1- vs 3-month DAPT, integration with bleeding/ischemic risk scores and newer stent technologies.
IMPORTANCE: The optimal duration of dual antiplatelet therapy (DAPT) in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI) remains uncertain. OBJECTIVES: To evaluate the safety and efficacy of abbreviated DAPT durations in patients at HBR undergoing PCI. DATA SOURCES: PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched from inception to October 26, 2025. STUDY SELECTION: Randomized clinical trials (RCTs) comparing abbreviated (ie, 1- to 3-month) vs standard (ie, 6- to 12-month) DAPT durations in patients at HBR without an indication for oral anticoagulation. DATA EXTRACTION AND SYNTHESIS: A pairwise meta-analysis was performed to compare abbreviated (ie, 1-month to 3-month) vs standard (ie, ≥6-month) DAPT durations. A frequentist network meta-analysis was performed to compare 1-month, 3-month, and standard DAPT.
3. Lipoprotein(a), Inflammation, and Risk of Coronary Artery Disease and Aortic Valve Stenosis.
Among 43,512 UK Biobank participants followed a median 13.5 years, IL-6 levels modified Lp(a)-associated CAD risk: HR for Lp(a) ≥125 nmol/L vs <125 nmol/L was 1.43 in IL-6 quartile 4 vs 1.09 in quartile 1 (Pinteraction=0.008). No inflammatory biomarker modified Lp(a)-associated AS risk.
Impact: Identifies IL-6 as a modifier of Lp(a)-associated CAD risk in primary prevention, advancing biomarker-driven, inflammation-informed risk stratification.
Clinical Implications: Combined assessment of Lp(a) and IL-6 may refine CAD risk stratification and inform dual-pathway interventions (Lp(a) lowering and anti-inflammatory strategies).
Key Findings
- Cohort of 43,512; median follow-up 13.5 years for CAD and 13.6 years for AS.
- IL-6 modified Lp(a)-associated CAD risk: HR 1.43 (Q4 IL-6) vs 1.09 (Q1 IL-6); Pinteraction=0.008.
- No inflammatory biomarker, including IL-6, modified Lp(a)-associated AS risk.
- Suggestive but non-significant interaction for NLR after multiple testing correction.
Methodological Strengths
- Large, well-characterized population cohort with proteomic profiling and long follow-up.
- Multivariable Cox modeling with formal interaction testing and multiple biomarker evaluation.
Limitations
- Observational design limits causal inference; residual confounding possible.
- Proteomic measures and IL-6 quartiles may not translate directly to clinical thresholds.
Future Directions: Test whether IL-6 pathway inhibition modifies event reduction in patients with elevated Lp(a); integrate Lp(a) and inflammatory markers into calibrated risk tools.
IMPORTANCE: Clinical heterogeneity exists among individuals with elevated lipoprotein(a) [Lp(a)] levels. Prior studies suggest that low-grade inflammation may modify this risk, but results remain conflicting. OBJECTIVE: To test the hypothesis that inflammatory biomarkers may modify Lp(a)-associated risk for coronary artery disease (CAD) and aortic valve stenosis (AS) in a primary prevention population. DESIGN, SETTING, AND PARTICIPANTS: Recruitment occurred between March 2006 through October 2010 among a population-based cohort of UK adults. UK Biobank participants without prevalent CAD or AS who underwent plasma proteomic profiling at study entry were eligible for inclusion. Data were analyzed from June 2025 through April 2026. EXPOSURES: Lp(a) levels (<125 nmol/L vs ≥125 nmol/L) and inflammatory biomarkers interleukin 1β (IL-1β), IL-18, IL-6, and the neutrophil to lymphocyte ratio (NLR).